Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2327949 in CKD
NCT04661917Phase 2Withdrawn
- Sponsor
- Bayer
- Start
- May 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) and diabetic kidney disease (DKD) comparing BAY 2327949 with Placebo (2 arms). Primary endpoint: Urine albumin-to-creatinine ratio at 28 days. Planned start May 2021; status: withdrawn.
02
Drugs
enuvaptan
03
Conditions
chronic kidney disease (CKD)diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT04661917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661917.